Drug News—November/December 2022A review of new launches, new indications, new dosage forms and Health Canada advisories. Sumatriptan identified as highest-risk drug leading to acute angle-closure glaucoma Large Korean study pinpoints 61 drugs associated with acute angle-closure glaucoma. Two new biosimilar insulins now available in Canada Viatris is introducing Kirsty (insulin aspart) and Semglee (insulin glargine). Tezspire now available for add-on maintenance treatment of severe asthma First biologic for severe asthma targeting thymic stromal lymphopoietin is effective regardless of phenotype. Breztri Aerosphere now available for long-term maintenance treatment of COPD Second 'triple-therapy' combination product approved in Canada for COPD maintenance treatment to reduce exacerbations and treat airflow obstruction. Will angiotensin receptor II blockers play a role in epilepsy prevention? Study examines whether ARB therapy is associated with a decreased incidence of new onset epilepsy in patients with hypertension. Health Canada approves two therapies for COVID-19 treatment Single-dose Evusheld is now indicated for treating mild/moderate COVID-19 and Actemra IV is now approved for treating COVID-19 in hospitalized adults. Preservative-free eyedrops now available in Canada Alcon's newest product for dry eye clinically demonstrated to provide all-day symptom relief. Drug News—August/September 2022 A review of new launches, new indications, new dosage forms and Health Canada advisories. Drug News—June/July A review of new launches, new indications, new dosage forms and Health Canada advisories. First Previous 35 36 37 Next Last
